Dyne Therapeutics, Inc. DYN

DYN Company Overview

Dyne Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing targeted therapies for serious neuromuscular diseases caused by genetic mutations. The company operates within the biotechnology and rare disease therapeutics industries, with a particular emphasis on muscle-related disorders where existing treatments have limited efficacy. Dyne’s core strategy centers on improving drug delivery to muscle tissue to enhance therapeutic outcomes.

The company’s primary value driver is its proprietary FORCE™ platform, which is designed to enable targeted delivery of therapeutic payloads, such as antisense oligonucleotides, to muscle cells. Dyne primarily serves patients with rare neuromuscular diseases, including myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD). Founded in 2018 and headquartered in Cambridge, Massachusetts, Dyne was established by scientists and industry veterans seeking to address limitations in muscle drug delivery. The company completed its initial public offering in 2020 and trades on the Nasdaq under the ticker DYN.